Auris Medical concludes enrolment in Phase III trial of Keyzilen for tinnitus

Swiss biopharmaceutical firm Auris Medical has concluded patient enrolment in a Phase III clinical trial (TACTT3) of its product candidate Keyzilen to treat acute and post-acute inner ear tinnitus.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news